alectinib sensitve ALK mutants [plasma membrane]

Stable Identifier
Set [DefinedSet]
Homo sapiens
Locations in the PathwayBrowser
Literature References
PubMed ID Title Journal Year
26372962 Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Deininger, MW, Vellore, NA, Eide, CA, Davare, MA, Goodman, JR, Druker, BJ, O'Hare, T, Drilon, A, Wagner, JP

Proc. Natl. Acad. Sci. U.S.A. 2015
26464158 ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression

Klempner, SJ, Ali, SM, Ou, SH, Milliken, JC, Miller, VA, Azada, MC

Lung Cancer 2016
25421750 Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma

Piazza, R, Ceccon, M, Giudici, G, Mologni, L, Fontana, D, Gambacorti-Passerini, C, Pirola, A

Mol. Cancer Res. 2015
25393796 Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib

Azada, M, Klempner, SJ, Schrock, AB, Ali, SM, Ou, SH, Stephens, PJ, Miller, VA, Ross, JS, Greenbowe, JR

J Thorac Oncol 2014
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!